Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike.
Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.